Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

ClinicalTrials.gov ID: NCT06822426

Public ClinicalTrials.gov record NCT06822426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)

Study identification

NCT ID: NCT06822426
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: CorMedix; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Central Line Associated Blood Stream Infections (CLABSI)

Interventions

(taurolidine and heparin) catheter lock solution Drug
Heparin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 13, 2025
Primary completion: Dec 31, 2026
Completion: Dec 31, 2026
Last update posted: Dec 23, 2025

2025 – 2027

United States locations

U.S. sites: 15
U.S. states: 15
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of California Los Angeles	Los Angeles	California	90024	Recruiting
MedStar Health Research Institute	Washington D.C.	District of Columbia	20010	Recruiting
Bioresearch Partner	Doral	Florida	33122	Recruiting
Emory University Hospital - GCRC	Atlanta	Georgia	30322	Recruiting
University of Iowa Health Care	Iowa City	Iowa	52242	Recruiting
Johns Hopkins Clinical Research Unit	Baltimore	Maryland	21205	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	68198-3285	Recruiting
Columbia University Irving Medical Center	New York	New York	10032	Recruiting
Duke University Hospital	Durham	North Carolina	27710	Active, not recruiting
Cleveland Clinic Foundation	Cleveland	Ohio	44195	Recruiting
Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
Vanderbilt Center for Human Nutrition	Nashville	Tennessee	37212-1150	Recruiting
Alchemi - Sugarland	Sugar Land	Texas	77478	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06822426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 23, 2025 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06822426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →